MCM
BCRX icon

Moore Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Moore Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48M Buy
+848,336
New +$7.67M 0.13% 148
2023
Q1 		– Sell
-65,000
Closed -$746K – 495
2022
Q4 		$746K Buy
+65,000
New +$811K 0.02% 343

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Moore Capital Management's BCRX Position: Q2 2026 in Review

Moore Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 848,336 shares worth $8.48M. The stake represents 0.13% of the portfolio and ranks #148 among its holdings. This is a return to the name: Moore Capital Management previously reported a position in BCRX as recently as Q4 2022.

Moore Capital Management first reported a position in BCRX in Q4 2022 and has held it in 2 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Moore Capital Management held 848,336 shares of BioCryst Pharmaceuticals worth $8.48M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Moore Capital Management position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.13% of Moore Capital Management's portfolio in Q2 2026, its #148 holding.
  • Moore Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2022 and has held it in 2 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.